– USA, CA – Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of industry veteran Marc Stapley to its Board of Directors as CEO effective June 1, 2021, succeeding co-founder, Bonnie Anderson who will into the Executive Chairman role.
“On behalf of the entire board of directors at Veracyte, we welcome Marc to the company in the CEO role. His broad global leadership experience, proven track record of strategic execution and strong commercial expertise makes him well suited to lead the company forward, with Bonnie at his side. There is a lot of work ahead of us and we are delighted to have Marc’s leadership as we enter this next phase of Veracyte’s growth.” said John Bishop, lead independent director.
“We are thrilled that Marc has agreed to join Veracyte as CEO and I am excited to work closely with him to achieve our vision and guide the company to achieve its full potential.” said current chairman and CEO, Bonnie Anderson.
Ms. Anderson cofounded Veracyte in 2008 and served as its president and CEO until 2016 when she was also appointed chairman of the board. She led Veracyte’s IPO in 2013, has spearheaded the commercialization of its market-leading products, and has overseen the company’s global expansion.
About Marc Stapley
Marc Stapley will join Veracyte from his current role as the chairman and CEO of Helix, Inc., a leading population genomics company. Under Mr. Stapley’s leadership, Helix has built one of the largest COVID-19 testing labs in the United States and has become a national leader in viral surveillance. Mr. Stapley was appointed CEO in April 2019 and has been a member of Helix’s board of directors since 2015, when the company was founded.
Before Helix, Mr. Stapley served in key executive leadership positions at Illumina, Inc., the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. While at Illumina, Mr. Stapley served as CFO, chief administrative officer, and executive vice president over the course of seven years, where he led many functions including G&A, corporate strategy, business development, population genomics, and government affairs.
Before joining Illumina, Mr. Stapley was senior vice president, finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts for key acquisitions and providing oversight to the company’s largest technology investment program. Before that, he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc, and Coopers & Lybrand.
“Veracyte is uniquely positioned in the genomic testing market with its breadth and depth of offerings, centralized and distributed tests, significant global opportunity, and highly talented team,” said Mr. Stapley. “Bonnie and the Veracyte team have put in place the key strategic pieces upon which to build and execute on multiple avenues of growth. I look forward to bringing my industry experience to bear as we forge ahead with our global expansion plans and improve outcomes for patients worldwide.”
About Veracyte
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
For more information: https://www.veracyte.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
